Previous close | 1.5400 |
Open | 1.5500 |
Bid | 0.0000 x 1400 |
Ask | 0.0000 x 3200 |
Day's range | 1.5200 - 1.7300 |
52-week range | 1.4300 - 5.6500 |
Volume | |
Avg. volume | 597,601 |
Market cap | 25.819M |
Beta (5Y monthly) | 0.94 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.9800 |
Earnings date | 14 May 2024 - 20 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.33 |
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.43. Palatin Technologies, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome […]
Q2 2024 Palatin Technologies Inc Earnings Call